Medicare IVIG Access Enhancement Act

The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS.

Client expense: $140,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs.

Client expense: $150,000 · Firm income: Not reported

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

Client expense: $130,000 · Firm income: Not reported

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees

Client expense: $210,000 · Firm income: Not reported

Medicare home infusion coverage Educational meetings on Grifols and presence in district/state H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1194, Medical Nutrition Equity Act; H.R. 4724

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: Not reported

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: Not reported

H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act

Client expense: $140,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

Medicare home infusion coverage Educational meetings on Grifols and presence in district/state H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 "Medicare IVIG Access Enhancement Act" Medicare home infusion coverage and reimbursement

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Domestic healthcare issues relate to coverage, reimbursement, and home infusion care; H.R.4724

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues.

Client expense: $140,000 · Firm income: Not reported

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act. Policies affecting pre-existing condition protections.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $230,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: Not reported · Firm income: $52,500

Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE

Patient's Access to Treatments Act GBS/CIDP research at NIH FDA, Patient Focused Drug Development Initiative Access to Marketplace Insurance Act CIDP, MMN Home Infusion Healthcare Reform, Patient Protections H.R. 4724

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids). S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: Not reported · Firm income: $52,500

Government targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs.

Client expense: $160,000 · Firm income: Not reported

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724--The Medicare IVIG Access Enhancement Act--Legislation that would create a home infusion benefit under Medicare Part B for intravenous immunoglobulin (IVIG) when used in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information. CMS memo re: Medicare Advantage plans authorized to employ step therapy for Part B drugs--Educating congressional staff as to the access concerns this new policy will have for patients reliant on Part B therapies NIH Appropriations funding/DoD Medical Research funding - specific to hereditary angioedema FY 2019 NIH Appropriations - seeking congressional letter identifying NIH funding spent on hereditary angioedema/maintaining hereditary angioedema on the list of conditions for the Dept. of Defense Peer Reviewed Medical Research Program Resolution to Affirm the Importance of the Orphan Drug Act--Building support for introduction of a resolution to affirm the importance of the Orphan Drug Act

Client expense: $290,000 · Firm income: Not reported

H.R. 4724 "Medicare IVIG Access Enhancement Act" Educational meetings about Grifols and presence in district/state

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 Medicare IVIG Access Enhancement Act

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare home infusion coverage Educational meetings on Grifols and presence in district/state H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act. Policies affecting pre-existing condition protections.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Domestic healthcare issues relate to coverage, reimbursement, and home infusion care; H.R. 4724

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patient's Access to Treatments Act GBS/CIDP research at NIH FDA, Patient Focused Drug Development Initiative Access to Marketplace Insurance Act CIDP, MMN Home Infusion Healthcare Reform, Patient Protections H.R. 4724

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare home infusion coverage Educational meetings on Grifols and presence in district/state H.R. 4724, Medicare IVIG Access Enhancement Act Babesia Awareness and Screening at CDC and FDA for HCR

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 Medicare IVIG Access Enhancement Act

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 "Medicare IVIG Access Enhancement Act" Babesia awareness and screening Educational meetings about Grifols and presence in district/state

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project.

Client expense: $150,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE

H.R. 4724--The Medicare IVIG Access Enhancement Act--Lobbied in support of this legislation that would create a home infusion benefit under Medicare Part B for IVIG when used in the treatment of CIDP. Preserving Access to Orphan Drugs Act--Exploration of fine tuning orphan drug exclusion from the annual pharmaceutical fee Educating congressional staff specific to the value of drug therapies (drug pricing, value, access to therapies, etc.) as part of Administration drug pricing blueprint and request for information.

Client expense: $170,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163, HR 1892 - lobbied House and Senate, CMS on proper implementation of the legislation. H.R.4724 - Medicare IVIG Access Enhancement Act, technical assistance

Client expense: $80,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Domestic healthcare issues relate to coverage, reimbursement, and home infusion care; H.R. 4724

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare home infusion coverage Educational meetings on Grifols and presence in district/state H.R. 4724, Medicare IVIG Access Enhancement Act Babesia Awareness and Screening at CDC and FDA for HCR

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patient's Access to Treatments Act GBS/CIDP research at NIH FDA, Patient Focused Drug Development Initiative Access to Marketplace Insurance Act CIDP, MMN Home Infusion Healthcare Reform, Patient Protections H.R. 4724

Client expense: Not reported · Firm income: $10,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Drug safety and drug counterfeiting; drug importation; H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 "Medicare IVIG Access Enhancement Act" Educational meetings about Grifols and presence in district/state

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 4724 Medicare IVIG Access Enhancement Act

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.

Client expense: $210,000 · Firm income: Not reported

114th Congress HR 605/S. 275 - Reintroduction of The Medicare Home Infusion Site of Care Act HR 3178, S. 1738, HR 3163, HR 1892 - lobbied House and Senate for temporary transitional home infusion clinical services reimbursement H.R.4724 - Medicare IVIG Access Enhancement Act, technical assistance

Client expense: $130,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE